Ivermectin, once hailed as a breakthrough antiparasitic medicine and later thrust into controversy during the pandemic, is regaining attention — this time among some cancer patients searching for alternative treatments. Although the drug remains highly effective against specific parasitic infections, medical experts warn that its expanding use beyond approved indications is not supported by strong clinical evidence.
Originally developed in the 1970s, ivermectin earned global recognition for reducing river blindness and other tropical diseases. The Nobel Prize in Physiology or Medicine was awarded in 2015 to scientists involved in its discovery, cementing its reputation as a transformative therapy. In humans, ivermectin treats infections such as strongyloidiasis and scabies, while in veterinary medicine it is widely used to combat parasites in livestock.
Prescriptions Rise Again After Pandemic Surge
During the early stages of COVID-19, ivermectin prescriptions soared to nearly 10 times pre-pandemic levels as some physicians prescribed it off-label. Subsequent large-scale studies, however, found no convincing evidence that the drug effectively treated or prevented COVID-19. Regulatory agencies, including the Food and Drug Administration, cautioned against its misuse and warned that excessive doses could cause side effects such as dizziness, nausea, low blood pressure, and in severe cases, coma.
Although prescriptions declined after the pandemic’s peak, researchers tracking prescribing trends report a renewed uptick beginning in 2024 and continuing into 2025. Much of this resurgence appears concentrated in politically conservative regions, where skepticism toward traditional medical guidance remains strong.
Several state legislatures — including Tennessee, Arkansas, Idaho, Louisiana, and Texas — have approved measures allowing ivermectin to be sold over the counter. Physicians have voiced concern that easier access may lead patients to self-medicate without professional oversight, potentially substituting ivermectin for established therapies.
Cancer Claims Spread Despite Limited Evidence
Interest in ivermectin has recently expanded into oncology circles, fueled in part by public figures and social media discussions suggesting it could fight cancer. Laboratory experiments have explored whether ivermectin might inhibit certain cancer cell pathways, but such findings remain preliminary and confined largely to test-tube and animal models.
The National Cancer Institute has acknowledged preclinical research examining various compounds, including ivermectin, for potential anti-cancer properties. Yet oncologists emphasize that most substances showing promise in early laboratory studies fail to demonstrate effectiveness in human clinical trials.
Doctors report that some patients now arrive at consultations asking about ivermectin as a primary treatment option. In rare cases, individuals have postponed chemotherapy or immunotherapy in favor of antiparasitic regimens promoted online. Specialists warn that abandoning evidence-based therapies can allow aggressive cancers to progress unchecked.
The American Cancer Society, through its cancer treatment guidelines, underscores the importance of therapies backed by rigorous clinical testing. These include targeted immunotherapies, hormone treatments, radiation, and chemotherapy protocols refined over decades of research.
Medical professionals say that while patients’ desire for hope is understandable, substituting unproven remedies for validated treatments poses significant risks. Ivermectin remains a valuable medication when used for approved indications, but its growing reputation as a cure-all — from viral infections to advanced cancers — continues to divide public opinion and challenge healthcare providers navigating increasingly politicized conversations in exam rooms.
